

1 Evaluation of a Multiplexed Immunoassay for Assessing Long-Term Humoral 2 Immunity to Monkeypox virus infection and Orthopoxvirus Vaccination

3
4 Bethany Hicks^{1*}, Scott Jones¹, Helen Callaby^{2,8}, Daniel Bailey², Claire Gordon², Tommy Rampling², Catherine
5 Houlihan², Ezra Linley⁷, Simon Tonge⁷, Clarissa Oeser⁶, Rachael Jones³, Marcus Pond⁴, Ravi Mehta⁴, Deborah
6 Wright⁵, Bassam Hallis¹, Cathy Rowe¹, Ashley Otter¹

7
8 ¹Emerging Pathogen Serology Group, Vaccine Development Evaluation and Preparedness Centre, UK Health
9 Security Agency, Porton Down, Wiltshire, UK

10 ²Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK

11 ³Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

12 ⁴Imperial College Healthcare NHS Trust, London, UK

13 ⁵Research and Development, UK Health Security Agency, Porton Down, Wiltshire, UK

14 ⁶Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, Colindale, London, UK

15 ⁷Seroepidemiology Unit, UK Health Security Agency, Manchester, UK

16 ⁸The Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

17
18 *Corresponding author: bethany.hicks@ukhsa.gov.uk

19 Abstract

20 In the summer of 2022, a large outbreak of Monkeypox virus (MPXV) cases occurred globally.
21 By December 2022, a total of 3,582 Mpox cases had been confirmed within the UK. As a
22 result, the Modified Vaccinia Ankara-Bavarian Nordic (“IMVANEX”) vaccine was offered to
23 high-risk groups to protect against the spread of the virus. This outbreak led to the
24 development of multiple serological assays to aid the current understanding of Mpox
25 immunology. This study assessed the performance of a multiplexed solid-phase
26 electrochemiluminescence (Meso Scale Discovery (MSD)) immunoassay for simultaneous
27 detection of antibodies against MPXV A29, A35, B6, E8, and M1 antigens, along with the
28 corresponding Vaccinia Virus (VACV) homologues A27, A33, B5, D8, and L1. Sensitivity and
29 specificity were evaluated with paediatric negatives (n=215), pre- and post-IMVANEX
30 vaccinated (n=80) and MPXV (2022 Clade IIb outbreak, n=39) infected serum samples. The
31 overall Orthopoxvirus multiplex assay demonstrated high specificity ranging from 75.68% (CI:
32 69.01-81.29) - 95.98% (CI:92.54-97.87) and sensitivity from 62.11% (CI:52.06-71.21) -
33 98.59% (CI:92.44% - 99.93%) depending on the Orthopoxvirus antigen, either used singularly
34 or combined. Additionally, preferential binding was observed between Mpox-infected
35 individuals and MPXV antigens, whilst vaccinated individuals exhibited increased binding to
36 VACV antigens. These results highlight the differential binding patterns between antigen
37 homologues in closely related viruses. Using this assay, we show that the Orthopoxvirus MSD
38 assay is highly sensitive in detecting IgG titres for vaccinated sera ≥ 24 -days post dose one
39 and ≥ 14 -days post dose two for all antigens within the assay except for MPXV A29 and VACV
40 A27. A similar trend was observed with convalescent sera, although differing antigens
41 demonstrate stronger sensitivities. Overall, this assay has the capability to accurately assess
42 antibody titres for multiple relevant MPXV and VACV antigens post infection and post
43 vaccination, demonstrating its utility in understanding immune responses to Orthopox viruses
44 in current and future outbreaks, and assessing the immunogenicity of new generation
45 Orthopox and Mpox-specific vaccinations.
46

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 Introduction

48 MPXV is a zoonotic Orthopoxvirus (OPXV) characterised as a large dsDNA virus with
49 a genome encoding over 200 different proteins¹. This complex antigenic profile poses
50 challenges with serological discrimination due to increased cross-reactivity of surface
51 proteins. Furthermore, MPXV has two closely related clades; Clade I (formerly Congo
52 Basin), and Clade II (formerly West African)², whereby Clade IIb was the primary clade
53 in the recent 2022 Mpox outbreak in various non-endemic countries³⁻⁵.

54

55 Vaccinia virus (VACV)^{6,7} has been essential in the development of various licensed
56 smallpox vaccines⁸, which was successfully implemented to eradicate smallpox in the
57 1980s⁹. This eradication was possible due to the immunogenicity of VACV and its
58 ability to provide cross-protection against additional Orthopoxviruses including
59 Monkeypox Virus (MPXV), Cowpox virus (CPXV) and Variola virus (VARV)¹⁰. During
60 the 2022 Mpox outbreak it was estimated that the efficacy of one IMVANEX
61 vaccination dose against MPXV is $\geq 78\%$ ¹¹⁻¹⁴.

62

63 It has been demonstrated that the recent second and third-generation Smallpox
64 vaccines (ACAM2000 and IMVANEX, respectively) produce a similar antigenic
65 response to MPXV infection¹⁵. This parallel immune response allows antibodies to
66 bind to numerous MPXV and VACV antigens due to the high sequence homology in
67 these proteins. Likewise, OPXV-elicited antibodies have increased cross-neutralising
68 capability than other virus families¹⁶, although the research on discriminatory antigens
69 and post-infection or vaccination immunity specific to MPXV antigens remain limited
70 ^{15,17,18}.

71 Surface proteins between VACV and MPXV-2022 exhibit approximately 94-98%
72 sequence similarity¹⁷. During inter-host transmission, the mature virion is dominant
73 where ~25 membrane proteins are expressed, including MPXV A29 and E8 with VACV
74 homologues A27 and D8 with an additional six proteins on the envelope (including
75 MPXV A35 and M1)¹⁸ that play a dominant role in the intra-host transmission¹⁹. Due
76 to the diverse number of immunodominant antigens, this initiated an increase in assay
77 development by diverse groups and manufacturers to enable investigation of trends in
78 serosurveillance, identification of MPXV cases, and evaluation of vaccine antibody
79 waning necessitating booster doses^{15,20,21}. However, many assays remain limited to

80 single-plex, restricting the simultaneous evaluation of multiple antigens in a single well.
81 Recognised for its high sensitivity multiplex capabilities, Meso Scale Discovery (MSD)
82 developed an Orthopoxvirus assay that measures IgG antibody responses to five
83 MPXV and five VACV immunodominant antigens. These range from cell adhesion
84 through either binding chondroitin sulphate (MPXV E8 and VACV D8)²² or heparan
85 sulphate (MPXV A29 and VACV A27)^{23,24}, whereas MPXV B5 and VACV B6 are
86 Extracellular Envelope virus (EEV)²⁵ which have been identified to be a target for EEV-
87 neutralising antibodies²⁶.

88
89 A multiplex assay such as the Orthopoxvirus MSD panel described here enables
90 higher-throughput screening of samples for quantifying antigen-specific antibodies.
91 However, with next-generation Smallpox or Mpox-specific vaccines such as mRNA²⁷,
92 there is a need for more discrete immunology assays than using MVA or whole-virus
93 serology assays. Here, we demonstrate the sensitivity and specificity of the MSD
94 Orthopoxvirus assay that simultaneously measures IgG to five MPXV (A29, A35, B6,
95 E8 and M1) and five VACV antigens (A27, A33, B5, D8 and L1).

96 Materials and Methods

97 Sample collection

98 *Serum samples*

99 Sera were obtained from individuals with an IMVANEX vaccination (n= 9 post-dose 1
100 (PD1), n=65 post dose 2 (PD2)), recruited from UKHSA Porton Down. Individuals were
101 bled 24 days after dose one, then 14 days after dose two followed by approximate
102 monthly bleeds up to 220 days after dose two. Anonymised Mpox convalescent serum
103 (n=39) was obtained from PCR-confirmed infection from the 2022 outbreak (Clade IIb)
104 from the Rare and Imported Pathogens Laboratory, Imperial College Healthcare NHS
105 Trust and Chelsea and Westminster Hospital NHS Foundation Trust. To determine the
106 assays specificity paediatric samples (n=215) from the UK Health Security Agency
107 (UKHSA) Seroepidemiology Unit (SEU) were sourced as negative samples.

108 **Meso Scale Discovery (MSD) IgG Electrochemiluminescence immunoassay** 109 **(ECLIA)**

110 The MesoScale Discovery V-PLEX Orthopoxvirus Panel 1 (K15688U-2)
111 electrochemiluminescence immunoassay (ECLIA) (MSD, Rockville, MD) was used to
112 specifically measure IgG antibody binding to five MPXV (A29L, A35R, B6R, E8L and
113 M1R) and five VACV (A27L, A33R, B5R, D8L and L1R) antigens in parallel in a 96-
114 well 10 spot plate format. MSD assays were performed as per the manufacturer's
115 instructions. Briefly, 96-well plates were blocked with MSD Blocker A, following plate
116 washing three times with 300 µl/well of PBS with Tween20 (0.01% final) using a Biotek
117 405 TS plate washer. Serum samples were diluted 1:1,000-10,000 in the
118 manufacturers diluent buffer before being added to the MSD plate, along with the
119 assay reference standard and controls. After incubation and a washing step, the
120 detection antibody (MSD SULFO-TAG™ Anti-Human IgG Antibody) was added to
121 each well. After further incubation and washing, MSD GOLD Read Buffer B was
122 added, and plates read using the MESO QuickPlex™ SQ 120. A standard curve was
123 established by fitting the signals from the standard using a 4-parameter logistic model.
124 Concentrations of samples were determined from the electrochemiluminescence
125 signals by back-fitting to the standard curve and multiplying by the dilution factor.
126 Antibody concentrations are expressed in Arbitrary Units/ml (AU/ml). Kits were

127 provided by MSD for evaluation purposes, with no involvement in the study design,
128 result interpretation, or manuscript writing.

129 **Statistical analysis**

130 Data analysis was performed using MSD Discovery Workbench 4.0 and GraphPad
131 Prism version 9.2.0 (GraphPad, San Diego, CA).

132 **Ethics**

133 IMVANEX Smallpox-vaccinated samples were obtained from individuals with written
134 consent through UKHSA Research and Ethics Committee for assay validation. Mpox
135 PCR-confirmed cases were granted approval for assay performance validation by the
136 NHS Research Ethics Committee (reference 22/HRA/3321) as described by Otter *et*
137 *al.*, 2023¹⁵.






138 Results

139 Evaluation of assay sensitivity and specificity for Orthopox vaccine and MPXV 140 serology

141 Receiver operator curves (ROC) were plotted to determine the sensitivity and
142 specificity using negatives against Mpox-infected and IMVANEX vaccinated samples
143 for each antigen (**Table 1** and **Figure 1**). In addition to determine the area under the
144 curve (AUC) to measure the accuracy of individual antigens. The AUC values were
145 calculated based on the performance of the antigens in discriminating between
146 negative and infected or vaccinated. Highest AUC values were observed for MPXV
147 B6, MPXV E8, VACV A33, VACV B5 and VACV D8, with an AUC comparable for all
148 antigens with a range of 0.76-0.99. **Table 1** indicates the positive/negative cut-offs for
149 each antigen determined from the ROC analysis using a likelihood ratio (LR)
150 calculation. MPXV A29 (62.11% (CI:52.06-71.21)) and its homologue VACV A27
151 (65.52% (CI:56.50-73.54)) were found to have much lower specificity and sensitivity
152 compared to the other antigens when comparing negative samples with vaccinated
153 and/or infected.

154
155 We next sought to assess ROC curves and therefore sensitivity and specificity for
156 individual cohorts, separating vaccinated (IMVANEX dose 1 and 2 vaccinated) and
157 MPXV convalescent sera (**Supplementary Table 1A & B**). Whilst specificity and
158 sensitivity remained consistent across most antigens, MPXV A29 and VACV A27,
159 showed higher sensitivity for MPXV convalescent sera in contrast to IMVANEX
160 vaccinated sera sensitivity: 88.89% (CI:74.69-95.59) and 57.69% (CI:46.62-68.04),
161 specificity: 90.09% (CI:85.45-93.36) and 69.82% (CI:63.49-75.48), respectively (**Table**
162 **1, Figure 1A**).

163
164 Conversely, MPXV M1 and VACV L1 demonstrated stronger sensitivity in detecting
165 antibody responses in IMVANEX vaccinated sera compared to Mpox-infected sera,
166 with a sensitivity of 91.30% (CI:82.30-95.95) and 81.58% (CI:66.58-90.78), and
167 specificity: 84.82% (CI:79.54-88.93) and 77.23% (CI:71.31-82.24), respectfully
168 (**Figure 1E, Table 1**).



170 **Figure 1: Receiver Operating Curves (ROC) for MPXV and VACV antigens, using negative samples as controls against**
171 **positive samples as either post-Mpox infected (“Infection”) and/or post-IMVANEX vaccination (“IMVANEX”).** ROC curves
172 demonstrating the sensitivity versus 100%-specificity of MPXV antigens with post-vaccination (Blue) or post-infection (Black) and
173 corresponding homologous VACV antigen with post-vaccination (Red) or post-infection (Green). Each homologous antigen pair from
174 the MSD assay are included: **(A)** MPXV A29 and VACV A27, **(B)** MPXV A35 and VACV A33, **(C)** MPXV B5 and VACV B6, **(D)** MPXV
175 E8 and VACV D8, and **(E)** MPXV M1 and VACV L1. Each solid line represents the ROC curve for the individual antigens and the
176 dotted red line represents the random classifier. Negative samples (n=215) were compared against post Mpox-infection (n=39) and
177 post IMVANEX vaccination samples (n=80).

178 **Table 1: Comparative analysis of sensitivity and specificity for multiple MPXV**
 179 **and VACV antigens using ROC analysis.** Sensitivity, specificity, and area under the
 180 curve (AUC) are stated for each individual antigen, as well as all 10 antigens combined
 181 based on the positivity score. Using paediatric negative (n=215) as controls, post
 182 Mpox-infection (n=39) and post IMVANEX vaccination (n=80) were compared.

183
 184

| Antigen | Cut-off | Sensitivity % | 95% CI | Specificity % | 95% CI | Likelihood Ratio | AUC |
|-------------------------|------------------|---------------|--------------------------|---------------|-------------------------|------------------|--------------|
| MPXV A29L | > 2.358 | 62.11 | 52.06% to 71.21% | 82.43 | 76.89% to 86.87% | 3.54 | 0.784 |
| VACV A27L | > 2.112 | 65.52 | 56.50% to 73.54% | 75.68 | 69.01% to 81.29% | 2.69 | 0.757 |
| MPXV A35R | > 2.752 | 91.60 | 85.22% to 95.37% | 90.63 | 86.09% to 93.79% | 9.77 | 0.969 |
| VACV A33R | > 6.349 | 93.28 | 87.29% to 96.55% | 95.54 | 91.98% to 97.56% | 20.89 | 0.985 |
| MPXV B6R | > 2.666 | 94.12 | 88.35% to 97.12% | 95.52 | 91.94% to 97.55% | 20.99 | 0.989 |
| VACV B5R | > 6.151 | 95.61 | 90.14% to 98.11% | 95.52 | 91.94% to 97.55% | 21.32 | 0.987 |
| MPXV E8L | > 22.20 | 98.59 | 92.44% to 99.93% | 95.98 | 92.54% to 97.87% | 24.54 | 0.989 |
| VACV D8L | > 25.99 | 96.25 | 89.55% to 98.98% | 97.77 | 94.88% to 99.04% | 43.12 | 0.988 |
| MPXV M1R | > 11.19 | 83.90 | 76.22% to 89.44% | 84.82 | 79.54% to 88.93% | 5.53 | 0.913 |
| VACV L1R | > 10.37 | 85.83 | 78.48% to 90.96% | 83.93 | 78.55% to 88.16% | 5.34 | 0.924 |
| All Ten Antigens | > 4.50 | 92.92 | 86.65 % to 96.37% | 93.98 | 89.98% to 96.45% | 15.44 | 0.970 |

185

186 **Utilising multiple antigens to determine Orthopox-positivity**

187 As a multi-antigen assay, we sought to determine the ability to classify samples as
188 positive based on the results to multiple antigens. Using the previously calculated cut-
189 off values for each antigen (**Table 1**), we applied these to a panel of positive
190 (vaccinated or infected) and negative samples, categorising samples as positive if they
191 were greater than the respective cut-off values for each antigen. If a sample was above
192 the cut off for each antigen, a value of one was assigned to it. The positivity count for
193 each sample was assessed on a scale out of ten due to the 10 antigens. Using ROC
194 analysis on negative versus positive samples, samples positive on 5 antigens resulted
195 in a sensitivity of 92.92% (CI:86.65-96.37) and specificity of 93.98% (CI:89.98-96.45)
196 (**Table 1**). Samples positive on greater than or equal to five antigens did not show an
197 improvement in sensitivity or specificity, whilst less than five resulted in both decreases
198 in sensitivity and specificity (**Supplementary Figure 2A**). This aligns with the
199 observed trends in AUC values among IMVANEX-vaccinated and/or Mpox-infected
200 individuals. For instance, the AUC ranges vary slightly across different cohorts, with
201 values ranging from 0.734-0.944 for IMVANEX-vaccinated, 0.946-0.963 for Mpox-
202 infected, and 0.807-0.950 for both cohorts combined. Notably, samples positive to five
203 or more antigens consistently exhibit increased AUC values, reaching an equilibrium
204 at approximately 0.97 (**Supplementary Figure 2A**).

205 **Comparative analysis of antibody titres to MPXV and VACV antigens across**
206 **cohorts**

207 The evaluation of antibody titres across various cohorts revealed evident patterns for
208 different antigens. Negative samples from paediatric samples predominantly
209 demonstrated median antibody titres below the corresponding cut-off values
210 (**Supplementary Table 2**). Most notably, the paediatric negative samples exhibited
211 significantly ($p < 0.00001$) lower antibody titres for all antigens except MPXV A29, A35,
212 B6 and VACV B5 (**Figure 2**). Post-dose 1 (PD1) median antibody titres for all antigens
213 were generally all positive; however, for MPXV A29, VACV A27, and MPXV A35, a
214 number of results were borderline with the identified cut-off value for individual
215 antigens (negative vs vaccination and Mpox-infected sera). Additionally, 14 days post-
216 dose two (PD2) and further subsequent time points up to 84 days post dose two,
217 significant increase in antibody levels was evident, displaying statistically significant
218 ($p < 0.00001$) differences from negatives for all antigens within the assay; MPXV A35,
219 B6, E8, M1 and VACV A27 ($p < 0.0001$), A33, B5, D8 and L1 (**Figure 2**).

220
221 Sera from vaccinated individuals were found to contain minimal antibodies directed
222 towards MPXV A29 and VACV A27 antigens, with low levels of positivity and only 56%
223 of positive samples exhibiting titres above the assigned cut-off value compared to
224 other antigens, such as MPXV E8 and VACV D8 in which 100% of positive samples
225 (vaccinated or infected) were found to be above the cut-off. Notably, positivity above
226 the cut-off decreased from 63 days (PD2.3) and 122 days (PD2.5) post-second dose
227 for MPXV A29 and VACV A27, with 0% positivity 157 days (PD2.6) and 185 days
228 (PD2.7) post-second dose for MPXV A29 and for VACV A27, respectfully.

229
230 Conversely, 95% of Mpox-infected individuals are above the cut-off for MPXV A29 and
231 VACV A27, with median antibody titres for these antigens at 96.07 AU/ml (CI:51.27-
232 234.70) for MPXV A29 and 64.52 AU/ml (CI:32.15-145.50) for VACV A27. Compared
233 to the average of all post-vaccination median values targeting these antigens, were
234 markedly lower at 1.05 AU/ml (CI:0.60-2.04) and 2.02 AU/ml (CI:0.91-3.38),
235 respectively (**Supplementary Table 2**).

236

237











238

239 **Analysis of serological reactivity to homologous MPXV/VACV proteins**

240 In a comparative analysis of protein homologues, we demonstrate a notable trend in
241 preferential binding between MPXV/VACV homologues (**Figure 3**). We observed that
242 sera from IMVANEX vaccinated individuals demonstrated preferential binding to
243 VACV A33, B5 and D8, compared to the corresponding MPXV homologues A35, B6
244 and D8. Furthermore, we reveal contrasting antibody responses among MPXV
245 convalescent sera compared to vaccine-induced sera. Mpox-infected individuals
246 exhibit a stronger antibody response to MPXV A29 compared to its antigen homologue
247 VACV A27 (**Figure 3A**). Mpox convalescent sera showed higher antibody levels
248 (AU/ml) against MPXV A29 and VACV A27, with a majority (94%) of samples positive
249 above the cut-off. Conversely, sera from vaccinated individuals demonstrated lower
250 antibody responses, with over half (56%) of results falling below the corresponding
251 cut-offs for these antigens (**Table 1**), parallel with the observations in **Figure 3A**.

252
253 Conversely, MPXV M1 and VACV L1 antigens showed a reverse trend whereby
254 IMVANEX-vaccinated individuals demonstrated preferential binding to VACV L1 rather
255 than MPXV M1. Specifically, antibody positivity levels among Mpox-infected
256 individuals were lower and border the cut-off value (24.64 AU/ml for MPXV M1 and
257 19.57 AU/ml for VACV L1, **Supplementary Table 2**). In contrast, vaccination-induced
258 antibody responses post dose two displayed >90% positivity above the cut-off, with
259 slightly lower positivity post dose one (78% and 89% against MPXV M1 and VACV L1,
260 respectfully). Whereas Mpox-infected sera which exhibited antibody levels clustering
261 around the cut-off, with 30% of samples falling below the threshold.

262
E)




263
264

Figure 2: Antigen specific analysis of antibody titres across various cohorts including negative, IMVANEX vaccinated and Mpox-22 infected individuals. Statistical significance was determined between positive cohorts against paediatric negatives (black asterisk) or against post dose one (PD1) (red asterisk) using an unpaired T test where * $p < 0.05$, ** $p < 0.001$, *** $p < 0.0001$, and **** $p < 0.00001$. The cut-off value for each antigen is represented by the dashed line. (A) MPXV A29, (B) MPXV A35, (C) MPXV B6, (D) MPXV E8, (E) MPXV M1, (F) VACV A27, (G) VACV A33, (H) VACV B5, (I) VACV D8 and (J) VACV L1.

265
266

267
268
269
270
271
272

273



274

275 **Figure 3: Correlation of post IMVANEX and MPXV convalescent sera to MPXV**
276 **and VACV protein homologues: A) VACV A27 and MPXV A29 B) VACV A33 and**
277 **MPXV A35 C) VACV B5 and MPXV B6 D) VACV D8 and MPXV E8 and E) VACV L1**
278 **and MPXV M1. The black dashed line response the corresponding cut-off for each**
279 **antigen.**

280

281 **Correlation between MXPV and VACV antigens**

282 Using Pearson correlation, we wanted to determine how antibody binding results for
283 each sample compare to one another for each VACV and MPXV antigen across Mpox-
284 infected and IMVANEX vaccinated individuals. We observe that homologous proteins
285 MPXV E8/VACV D8 and MPXV M1/VACV L1 showed the strongest correlation
286 **(Figure 4, Supplementary Table 3)**. In addition to the correlation observed between
287 the homologous proteins, we observed that some antigens were strongly correlated to
288 one another. In particular, MPXV A35/VACV A33 strongly correlated with VACV
289 B5/MPXV B6, whilst VACV L1/MPXV M1 correlated to VACV A33, VACV D8/MPXV
290 E8, and VACV B5/MPXV B6.

291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309




Figure 4: Two-tailed Pearson correlation analysis and heat map visualisation of significant correlations for antibody binding to each MPXV or VACV antigens for vaccinated and/or infected individuals. Blank cells represent non-significant ($p \geq 0.05$) correlations.

310 Discussion

311 In response to the global Mpox outbreak in 2022, a number of assays have been
312 developed to assess both immune responses to MPXV infection and Smallpox
313 vaccination^{20,28}. Accurate assays for detecting MPXV and VAVC antibodies are critical
314 for evaluating new vaccinations and for conducting serosurveillance studies to
315 determine exposure to MPXV and those previously vaccinated, especially with
316 ongoing Mpox infections in Europe, America and Asia, in addition to high-incidence
317 countries such as DRC and Nigeria²⁹.

318
319 This study aimed to evaluate the sensitivity and specificity of the MSD Orthopoxvirus
320 10-plex assay, coated with immunodominant antigens MPXV M1, A35, B6 and A29
321 which have previously been identified to be highly immunogenic^{21,30-32}. We applied
322 this assay for the subsequent analysis of antibody titres across both infected and
323 IMVANEX (“JYNNEOS”) vaccination cohorts to provide an understanding of the
324 humoral immune responses to both MPXV and VACV antigens. We have
325 demonstrated this assay exhibits a high level of specificity and sensitivity in detecting
326 antibodies against MPXV and VACV antigens, revealing antigen specific immune
327 responses post infection and/or vaccination.

328
329 **Orthopoxvirus MSD panel demonstrates high sensitivity and specificity in**
330 **detecting Orthopoxvirus antibodies**

331 Individual median fluorescence intensity (MFI) cut-offs were determined for each
332 antigen using ROC analysis by comparing negatives against IMVANEX vaccinated
333 and Mpox-infected (**Supplementary Figure 1**). The sensitivity and specificity varied
334 across the ten antigens, with corresponding area under the curves (AUCs) ranging

335 from 0.757 (VACV A27) to 0.989 (MPXV E8). Certain antigens, such as MPXV A35,
336 B6 and E8, as well as VACV A33, B5 and D8, demonstrated high accuracy levels
337 (AUC values >0.96). This indicates the potential for these antigens in distinguishing
338 between vaccinated and/or Mpox-infected individuals to negative individuals.
339 However, when separating positive samples to either post Mpox-infected or post
340 IMVANEX vaccinated, it was evident specific antigens (MPXV A29, M1 and VACV
341 A27 and L1) have differences in sensitivity and specificity values (**Figure 1**). While
342 both MPXV M1 and VACV L1 exhibit AUC values >0.9, there is a small discrepancy
343 between post IMVANEX vaccination and post Mpox-infection towards the sensitivity
344 and specificity for these antigens. An ROC analysis evaluating paediatric negatives to
345 vaccinated sera reveals a higher sensitivity (91.3 % CI:82.30-95.95) compared to
346 those infected with Mpox (81% CI:66.58-90.78) and vaccinated and Mpox-infected
347 individuals combined (83.9% CI:76.22-89.44) (**Table 1, Supplementary Table 1**).
348 This demonstrates that individuals vaccinated with IMVANEX generate a higher M1
349 antibody response compared to those infected, consistent with findings from previous
350 studies²⁸. Additionally, it has been observed that mRNA vaccines (VGPOx1 and
351 VGPOx2, both encoding a fusion protein containing A35R and M1R) induce a rapid
352 and robust production of MPXV M1 and A35 specific antibodies seven days after
353 vaccination, indicating a more effective immune response to MPXV M1 compared to
354 natural infection which induced humoral immunity against other antigens with non-
355 significant levels of M1-specific antibodies seven days post exposure³³.

356
357 Similarly, MPXV A29 and VACV A27 demonstrated lower specificity and sensitivity,
358 emphasising potential limitations in distinguishing between positive and negative
359 samples for these antigens, although they had AUCs of 0.78 and 0.76, respectively,

360 indicating adequate accuracy. Likewise, Yates *et al.*²⁰ demonstrated that during the
361 development of a serological assay MPXV antigen A29 and its homologue VACV A27
362 had a low sensitivity and specificity with the AUC <0.80, which showed similarities with
363 the antigens in this multiplexed assay. Interestingly, with vaccinated samples removed
364 from the ROC analysis, this increases the specificity (89% (CI:74.69-95.59)) and
365 specificity (90% (CI:85.45-93.36)), and likewise for VACV A27 sensitivity (84%
366 (CI:78.39-88.86)) and specificity (88.89% (CL:74.69%-95.59)) increases (**Figure 1A**).
367 This suggests there could be variation in the immune response between convalescent
368 individuals and those who received the IMVANEX vaccination for this antigen. It has
369 been identified that MPXV A29 is the main antigen used in immunoassays for MPXV
370 due to its location on the envelope³⁴, this suggests that individuals infected with MPXV
371 would likely generate a higher antibody response to MPXV A29 compared to those
372 vaccinated, as seen in this assay (**Figure 2A**). Likewise, MPXV A29 (along with
373 additional MPXV proteins A35, M1 and B6) have been identified to generate a CD4+
374 T cell cellular response and are one of the primary targets of neutralising
375 antibodies^{21,35}.

376

377 **Determining optimal assay cut-offs for detecting broad and specific** 378 **Orthopoxvirus antibodies**

379 This assay shows that samples positive to 1 - 4 antigens have a lower specificity and
380 sensitivity compared to ≥ 5 antigens (**Supplementary Figure 2A**). The cut-off of ≥ 5
381 antigens demonstrate a high sensitivity (93% CI:86.65-96.37) and specificity (94%
382 CI:89.98-96.45), whilst evaluating different cohorts (convalescent versus vaccinated)
383 to assess if an individual is positive to Orthopox antibodies. Whilst a limited number of
384 commercial assays exist for Mpox serology, the MSD multiplex assays offers a unique

385 opportunity to assess antibody titres to individual antigens but also through our
386 classification method described here can be used for inferring the Orthopox-specific
387 immune status. With the established assay cut-off, this can be used to classify
388 individuals as positive or negative for Orthopoxvirus antibodies should they be above
389 the identified cut off for ≥ 5 antigens. This established assay offers a promising tool for
390 both diagnostic and serosurveillance applications, thereby enhancing further
391 serological research around Mpox in an easy-to-use format. A number of additional
392 antigens could be included in future assay developments, such as MPXV A27 which
393 have been shown to be differential for vaccinated from infected^{15,36}.

394

395 **Orthopoxvirus-specific IgG antibody dynamics vary by antigen**

396 Across the MPXV/VACV antigens we observe that Smallpox-vaccination (IMVANEX)
397 induces a similar antibody response to those infected with MPXV Clade IIb. Due to
398 their cross protection (as well as high genetic and antigenic homology), Smallpox
399 vaccines have been used to prevent and reduce the severity of Mpox¹³. Although
400 currently the Orthopoxvirus MSD plates are limited to five antigen homologues, future
401 generations of Orthopoxvirus vaccines are likely to be antigen specific as with the
402 development of a number of multivalent mRNA vaccines^{27,37}, highlighting the necessity
403 for multiplex assays for Orthopoxvirus immunity testing.

404

405 Whilst the Mpox genome has >200 proteins, the MSD assay is limited to 10 antigens
406 in total (five of each MPXV and VACV homologous proteins), therefore other antigens
407 capable of generating an immune response could be undetected in this assay. For
408 instance, we previously demonstrated MPXV A27 as a potential discriminatory antigen
409 between infected and vaccinated individuals due the truncation of the A27L gene in

410 MVA-BN (IMVANEX)¹⁵. In addition, we demonstrated MPXV B2 as a primary
411 immunodominant antigen after one IMVANEX dose¹⁵. The inclusion of additional
412 antigens such as these in newer generation serological assays are paramount to
413 identifying antigens involved in protective immune responses against
414 Orthopoxviruses, as well as discriminating between vaccine- and infection-derived
415 immunity, both for vaccine and serosurveillance studies.

416

417 Similarly, although the MVA-BN vaccine primarily induced antibodies specific to MVA
418 and VACV, there is a limited correlation between MVA and MPXV neutralising
419 antibodies³⁸. This suggests antigenic differences among Orthopoxviruses, an area
420 that should be investigated further to evaluate vaccine immunogenicity and cross-
421 protection. Notably, this study only focused on Mpx Clade IIb, although it has been
422 observed there is no difference in antigen recognition between Clade IIa¹⁵, there are
423 mutational differences observed between variants³⁹ which could lead to divergent
424 immune responses, an area to be explored further. Especially with the continued
425 spread of Clade I Mpx evidenced by recent outbreaks in the Democratic Republic of
426 Congo²⁹.

427

428 Analysis of antibody titres revealed distinct patterns across cohorts, providing
429 essential information on the dynamics of the humoral immune response. Negative
430 samples predominantly exhibited antibody titres below the cut-off values for all
431 antigens, indicating either undetectable immune responses, or in those with low level
432 reactivity being presumed cross-reactive antibodies and background noise.
433 IMVANEX-vaccinated individuals post-dose one displayed an initial low, yet detectable
434 and significantly higher ($p < 0.00001$) immune response against MPXV E8, M1, and

435 VACV A27, A33, D8 and L1 antigens compared to negatives (**Figure 2**). However, the
436 lack of antibody responses indicated here does not suggest lack of protection, with
437 IMVANEX vaccine efficacy after one dose assessed as $\geq 78\%$ ¹¹⁻¹⁴.

438

439 A significant increase in antibody titres is observed for MPXV A35 ($p=0.021$), B6
440 ($p=0.026$), E8 ($p=0.022$) and VACV B5 ($p=0.042$), L1 ($p=0.022$) in relation to PD1, 14-
441 days from administration of the second dose (**Figure 2**), with VACV D8 ($p=0.038$)
442 demonstrating significant increases 43-days post second vaccination, suggesting a
443 necessity for a second dose, similarly observed in other (singleplex) assays^{15,16}.
444 Although it is shown antibodies are present, whether these antibodies provide
445 protection remains unanswered, emphasising the need for further investigation into
446 correlates of protection and antigen-specific responses on overall immunity.

447

448 Nevertheless, a subsequent decrease in antibody titres was observed ~84 days post-
449 dose 2 (PD2.4, **Figure 2**), suggesting a waning of the humoral immune response to
450 MPXV and VACV antigens. A similar trend that we previously demonstrated with
451 individual MPXV and VACV antigen ELISAs²⁸. The majority of samples remain above
452 the designated cut-off defined in this study up to 220 days post-dose two. After this,
453 median antibody titres decline for each antigen and are non-significantly different to
454 post dose one responses. MPXV A35 and B6 demonstrate the most pronounced
455 waning of immune responses post two doses of vaccination, specifically, antibody
456 titres wane to levels comparable to negative samples >185 days for MPXV A35
457 (PD2.7, **Figure 2B**) and >122 days for MPXV B6 (PD2.5, **Figure 2C**). The continued
458 waning of antigen-specific antibodies is being sought from ongoing longitudinal

459 investigations, using a panel of 12 MPXV-specific antigens, some of which can be
460 assessed through this MSD assay.

461

462 **Correlation between IMVANEX and Mpox-infected individuals against** 463 **MPXV/VACV homologous proteins**

464 As previously shown¹⁵ when comparing antigen homologues IMVANEX vaccinated
465 sera showed preferential binding to VACV A33, B5 and D8 and MPXV convalescent
466 sera to MPXV A35, B6 and E8, respectively. MPXV A35 and VACV A33 had the most
467 pronounced differentiation (**Figure 3**) which corresponds to findings observed in other
468 singleplex and multiplex ELISAs^{15,36}, highlighting that the type of antigen exposure
469 influences the subsequent antibody binding preference. All antigens within this assay
470 are MPXV and VACV homologous proteins, which could provide additional
471 mechanisms for differentiating between convalescent and vaccine-derived antibodies.
472 We observed that antibodies against MPXV A29 and VACV A27 were generally higher
473 in Mpox convalescent samples than those post-IMVANEX vaccination. MPXV A29 is
474 highly conserved between MPXV and VACV⁴⁰ with a 93.6% sequence identity with
475 VACV A27 homologue,⁴¹ so the observation of a decreased humoral immune
476 response to MPXV A29 is not known and warrants further investigation. Instances of
477 truncated proteins (e.g., MPXV A27) have been observed in the MVA-BN strain,
478 suggesting something similar may have occurred which could aid further aid in the
479 differentiation between infected, historically vaccinated and recently vaccinated.
480 However, whilst there are reduced antibody titres, these antigens activate cellular
481 immunity and produce neutralising antibodies, providing a level of protection²¹. Further
482 investigations into MPXV A29 and VACV A27 could provide a valuable insight into
483 immunity dynamics.

484 Conversely, with MPXV M1 and VACV L1 we observe antibody responses to these
485 antigens more evidently in those receiving the IMVANEX vaccine (**Figure 2**). MPXV
486 M1 has been identified as an important immunogen⁴² and has 98.8% sequence
487 homology with VACV L1⁴¹, suggesting that the robust antibody response of M1 should
488 be mirrored in the homologous VACV protein. Due to the robust antibody and T-cell
489 responses with MPXV M1²⁷, this has been included in candidate multivalent mRNA
490 Orthopoxvirus vaccine along with MPXV A35, B6 and H3. We have similarly confirmed
491 the observation of M1 (and therefore L1) antibodies being vaccination specific¹⁵,
492 warranting further investigation as to the mechanism as to why these are vaccination
493 specific. Finally, using Pearson correlation we observed the relationship between
494 MPXV/VACV antigens. All antigens are significantly correlated to their corresponding
495 homologue, with MPXV E8/VACV D8 exhibiting the strongest correlation (**Figure 4**,
496 **Supplementary Table 3**). Additionally, we observed correlations between certain
497 antigens such as MPXV A35/VACV A33 correlated with MPXV B6/VACV B5, as well
498 as MPXV M1/VACV L1 correlated to VACV A33, MPXV E8/VACV D8, and MPXV
499 B6/VACV B5. These correlations primarily involve immunodominant antigens^{15,21},
500 suggesting their importance and the relationship between different antigens in the
501 overall immune response to infection and vaccination.

502 **Conclusion**

503 Here we demonstrate the MSD Orthopoxvirus assay is highly sensitive, specific, and
504 reproducible for the detection of Orthopox-specific antibodies. This assay provides a
505 valuable tool for serosurveillance and in the assessment of new generation Orthopox
506 vaccine candidates as well as understanding Orthopoxvirus immunity. This assay
507 provides benefits over current singleplex assays in its ability to test multiple antigens
508 simultaneously, with opportunities for comprehensive studies and deeper insights into
509 the ongoing spread of Mpox worldwide.


510 References

- 511 1. Shchelkunov, S. N. *et al.* *Human Monkeypox and Smallpox Viruses: Genomic*
512 *Comparison*. (2001).
- 513 2. Chen, N. *et al.* Virulence differences between monkeypox virus isolates from
514 West Africa and the Congo basin. *Virology* **340**, 46–63 (2005).
- 515 3. Martín-Delgado, M. C. *et al.* Monkeypox in humans: a new outbreak. *Revista*
516 *Espanola de Quimioterapia* vol. 35 509–518 Preprint at
517 <https://doi.org/10.37201/req/059.2022> (2022).
- 518 4. Thornhill, J. P. *et al.* Monkeypox Virus Infection in Humans across 16 Countries
519 — April–June 2022. *New England Journal of Medicine* **387**, 679–691 (2022).
- 520 5. Isidro, J. *et al.* Phylogenomic characterization and signs of microevolution in the
521 2022 multi-country outbreak of monkeypox virus. *Nat Med* **28**, 1569–1572
522 (2022).
- 523 6. Lansiaux, E., Jain, N., Laivacuma, S. & Reinis, A. The virology of human
524 monkeypox virus (hMPXV): A brief overview. *Virus Res* **322**, (2022).
- 525 7. Petersen, E. *et al.* Human Monkeypox: Epidemiologic and Clinical
526 Characteristics, Diagnosis, and Prevention. *Infectious Disease Clinics of North*
527 *America* vol. 33 1027–1043 Preprint at <https://doi.org/10.1016/j.idc.2019.03.001>
528 (2019).
- 529 8. Weltzin, R. *et al.* Clonal vaccinia virus grown in cell culture as a new smallpox
530 vaccine. *Nat Med* **9**, 1125–1130 (2003).
- 531 9. Fenner, F., Henderson, D. A., Arita, I., Ježek, Z. & Ladnyi, I. D. ., 1987. Smallpox
532 and its eradication. Geneva: WHO, p.210. *Geneva: WHO, p.210*. 210 (1987).
- 533 10. Petersen, B. W., Harms, T. J., Reynolds, M. G. & Harrison, L. H. Use of Vaccinia
534 Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for
535 Occupational Exposure to Orthopoxviruses — Recommendations of the
536 Advisory Committee on Immunization Practices (ACIP), 2015. *MMWR Morb*
537 *Mortal Wkly Rep* **65**, 257–262 (2016).
- 538 11. Bertran, M. *et al.* Effectiveness of one dose of MVA–BN smallpox vaccine
539 against mpox in England using the case-coverage method: an observational
540 study. *Lancet Infect Dis* **23**, 828–835 (2023).
- 541 12. Saadh, M. J. *et al.* Progress and prospects on vaccine development against
542 monkeypox infection. *Microbial Pathogenesis* vol. 180 Preprint at
543 <https://doi.org/10.1016/j.micpath.2023.106156> (2023).
- 544 13. Gong, Q., Wang, C., Chuai, X. & Chiu, S. Monkeypox virus: a re-emergent threat
545 to humans. *Virologica Sinica* vol. 37 477–482 Preprint at
546 <https://doi.org/10.1016/j.virs.2022.07.006> (2022).
- 547 14. Dalton, A. F. *et al.* *Estimated Effectiveness of JYNNEOS Vaccine in Preventing:*
548 *A Multijurisdictional Case-Control Study — United, August 19, 2022–March 31,*
549 *2023*. (2023).

- 550 15. Otter, A. D. *et al.* Monkeypox virus-infected individuals mount comparable
551 humoral immune responses as Smallpox-vaccinated individuals. *Nat Commun*
552 **14**, (2023).
- 553 16. Cohn, H. *et al.* Mpox vaccine and infection-driven human immune signatures:
554 an immunological analysis of an observational study. *Lancet Infect Dis* **23**,
555 1302–1312 (2023).
- 556 17. Ahmed, S. F., Sohail, M. S., Quadeer, A. A. & McKay, M. R. Vaccinia-Virus-
557 Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the
558 2022 Monkeypox Virus. *Viruses* **14**, (2022).
- 559 18. Laliberte, J. P., Weisberg, A. S. & Moss, B. The membrane fusion step of
560 vaccinia virus entry is cooperatively mediated by multiple viral proteins and host
561 cell components. *PLoS Pathog* **7**, (2011).
- 562 19. Bengali, Z., Satheshkumar, P. S. & Moss, B. Orthopoxvirus species and strain
563 differences in cell entry. *Virology* **433**, 506–512 (2012).
- 564 20. Yates, J. L. *et al.* Development of a novel serological assay for the detection of
565 mpox infection in vaccinated populations. *J Med Virol* **95**, (2023).
- 566 21. Yang, X. *et al.* A Subunit Vaccine Candidate Composed of Mpox Virus A29L,
567 M1R, A35R, and B6R Elicits Robust Immune Response in Mice. *Vaccines*
568 (*Basel*) **11**, (2023).
- 569 22. Berhanu, A. *et al.* Vaccination of BALB/c Mice with Escherichia coli -Expressed
570 Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia
571 Virus Challenge . *J Virol* **82**, 3517–3529 (2008).
- 572 23. Lee, W., Kim, Y. J., Lee, S. J., Ahn, D. G. & Kim, S. J. Current Status of
573 Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging
574 Human Monkeypox Virus. *J Microbiol Biotechnol* **33**, 981–991 (2023).
- 575 24. Shi, D. *et al.* Kinetic and Structural Aspects of Glycosaminoglycan–Monkeypox
576 Virus Protein A29 Interactions Using Surface Plasmon Resonance. *Molecules*
577 **27**, (2022).
- 578 25. Roberts, K. L. *et al.* Acidic residues in the membrane-proximal stalk region of
579 vaccinia virus protein B5 are required for glycosaminoglycan-mediated
580 disruption of the extracellular enveloped virus outer membrane. *Journal of*
581 *General Virology* **90**, 1582–1591 (2009).
- 582 26. Bell, E. *et al.* Antibodies against the extracellular enveloped virus B5R protein
583 are mainly responsible for the EEV neutralizing capacity of vaccinia immune
584 globulin. *Virology* **325**, 425–431 (2004).
- 585 27. Zuiani, A. *et al.* A multivalent mRNA monkeypox virus vaccine (BNT166)
586 protects mice and macaques from orthopoxvirus disease. *Cell* (2024)
587 doi:10.1016/j.cell.2024.01.017.
- 588 28. Otter, A. D. *et al.* Analogous humoral antigen recognition between Monkeypox-
589 infected and Smallpox-vaccinated individuals. (2022)
590 doi:10.1101/2022.12.22.22283648.
- 591 29. Angel N. Desai *et al.* Implications of the 2023-2024 MPXV Clade I Outbreak in
592 the DRC to Global Public Health. *Clinical Microbiology and Infection* (2024).


- 593 30. Tang, D. *et al.* Recombinant proteins A29L, M1R, A35R, and B6R vaccination
594 protects mice from mpox virus challenge. *Front Immunol* **14**, (2023).
- 595 31. Davies, D. H. *et al.* Antibody Profiling by Proteome Microarray Reveals the
596 Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus
597 Ankara Is Comparable to That of Dryvax. *J Virol* **82**, 652–663 (2008).
- 598 32. Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. Quantification of antibody
599 responses against multiple antigens of the two infectious forms of Vaccinia virus
600 provides a benchmark for smallpox vaccination. *Nat Med* **12**, 1310–1315 (2006).
- 601 33. Hou, F. *et al.* mRNA vaccines encoding fusion proteins of monkeypox virus
602 antigens protect mice from vaccinia virus challenge. *Nat Commun* **14**, (2023).
- 603 34. Shi, D. *et al.* Kinetic and Structural Aspects of Glycosaminoglycan–Monkeypox
604 Virus Protein A29 Interactions Using Surface Plasmon Resonance. *Molecules*
605 **27**, (2022).
- 606 35. Grifoni, A. *et al.* Defining antigen targets to dissect vaccinia virus and
607 monkeypox virus-specific T cell responses in humans. *Cell Host Microbe* **30**,
608 1662-1670.e4 (2022).
- 609 36. Jones, S. *et al.* MpoXplex: a high-throughput and versatile multiplexed
610 immunoassay for assessing and discriminating between IgG responses to MpoX
611 infection and vaccination. *MedRxiv* (2024).
- 612 37. Freyn, A. W. *et al.* An MpoX Virus mRNA-Lipid Nanoparticle Vaccine Confers
613 Protection against Lethal Orthopoxviral Challenge. <https://www.science.org>
614 (2023).
- 615 38. Zaeck, L. M. *et al.* Low levels of monkeypox virus-neutralizing antibodies after
616 MVA-BN vaccination in healthy individuals. *Nat Med* **29**, 270–278 (2023).
- 617 39. Gigante, C. M. *et al.* Multiple Lineages of Monkeypox Virus Detected in the
618 United States, 2021-2022. <https://www.science.org> (2022).
- 619 40. Gao, F. *et al.* Cross-reactive immune responses to monkeypox virus induced by
620 MVA vaccination in mice. *Virology* **20**, (2023).
- 621 41. Shchelkunov, S. N. *et al.* Analysis of the monkeypox virus genome. *Virology*
622 **297**, 172–194 (2002).
- 623 42. Bisht, H., Weisberg, A. S. & Moss, B. Vaccinia Virus L1 Protein Is Required for
624 Cell Entry and Membrane Fusion. *J Virol* **82**, 8687–8694 (2008).
- 625
- 626

627 Supplementary Material



628
629 **Figure 1: Receiver Operating Curves (ROC) for MPXV (black) and VACV (blue)**
630 **homologous proteins.** Evaluating the sensitivity and specificity of homologues with
631 negative (n=215) versus Mpox-infected (n=39) and IMVANEX vaccinated (n=80)
632 individuals. **A) MPXV A29 & VACV A27, B) MPXV A35 & VACV A33, C) MPXV B6 &**
633 **VACV B5, D) MPXV E8 & D8 and E) MPXV M1 & VACV L.** Each solid line represents
634 the ROC for individual antigens, while the dashed red line is a random classifier.

635
636



637
638
639
640
641
642
643
644

Figure 2: Combined antigen ROC curves. A) Comparing negative versus either (i.) MPOX-infected & IMVANEX infected, (ii.) MPOX-infected or (iii.) IMVANEX vaccinated. Evaluating antigen positivity across a spectrum of one to ten antigens relative to cut-off values detailed in Table 1. B) ROC curve for all ten antigens based on positivity scores, for IMVANEX vaccinated, MPOX-infected and both combined.

645 **Table 1: Summary of ROC curves and individual antigen cut offs. A) Mpox-infected and B) IMVANEX vaccinated.** Cut-offs were
 646 generated but comparing all positive samples (either Mpox-infected (n=39) or IMVANEX vaccinated (n=80) with all negative samples
 647 to each MPXV/VACV antigen by ROC analysis.

| Antigen | Cut off | Sensitivity % | 95% CI | Specificity % | 95% CI | Likelihood Ratio | AUC |
|------------------------------|----------|---------------|------------------|---------------|------------------|------------------|--------|
| A) Mpox-Infected | | | | | | | |
| MPXV A29L (NEGS Vs MPXV) | > 6.976 | 88.89 | 74.69% to 95.59% | 90.09 | 85.45% to 93.36% | 8.97 | 0.938 |
| MPXV A35R (NEGS Vs MPXV) | > 37.09 | 94.29 | 81.39% to 98.98% | 99.11 | 96.80% to 99.84% | 105.61 | 0.981 |
| MPXV B6R (NEGS Vs MPXV) | > 6.706 | 94.59 | 82.30% to 99.04% | 97.31 | 94.26% to 98.76% | 35.16 | 0.986 |
| MPXV E8L (NEGS Vs MPXV) | > 23.83 | 94.44 | 74.24% to 99.72% | 95.98 | 92.54% to 97.87% | 23.51 | 0.975 |
| MPXV M1R (NEGS Vs MPXV) | > 6.852 | 81.58 | 66.58% to 90.78% | 77.23 | 71.31% to 82.24% | 3.58 | 0.856 |
| VACV A27L (NEGS Vs MPXV) | > 5.014 | 88.89 | 74.69% to 95.59% | 84.32 | 78.39% to 88.86% | 5.67 | 0.923 |
| VACV A33R (NEGS Vs MPXV) | > 9.251 | 89.47 | 75.87% to 95.83% | 96.88 | 93.69% to 98.48% | 28.63 | 0.989 |
| VACV B5R (NEGS Vs MPXV) | > 8.307 | 94.59 | 82.30% to 99.04% | 96.41 | 93.08% to 98.17% | 26.37 | 0.982 |
| VACV D8L (NEGS Vs MPXV) | > 11.84 | 93.55 | 79.28% to 98.85% | 95.54 | 91.98% to 97.56% | 20.95 | 0.974 |
| B) IMVANEX Vaccinated | | | | | | | |
| MPXV A29L (NEGS Vs IMVANEX) | > 0.9492 | 57.69 | 46.62% to 68.04% | 69.82 | 63.49% to 75.48% | 1.91 | 0.6756 |
| MPXV A35R (NEGS Vs IMVANEX) | > 2.752 | 89.19 | 80.09% to 94.42% | 90.63 | 86.09% to 93.79% | 9.51 | 0.9601 |
| MPXV B6R (NEGS Vs IMVANEX) | > 1.112 | 97.18 | 90.30% to 99.50% | 91.93 | 87.60% to 94.83% | 12.04 | 0.9887 |
| MPXV E8L (NEGS Vs IMVANEX) | > 22.20 | 100 | 92.29% to 100.0% | 95.98 | 92.54% to 97.87% | 24.89 | 0.9943 |
| MPXV M1R (NEGS Vs IMVANEX) | > 11.19 | 91.3 | 82.30% to 95.95% | 84.82 | 79.54% to 88.93% | 6.02 | 0.9391 |
| VACV A27L (NEGS Vs IMVANEX) | > 2.112 | 46.38 | 35.11% to 58.02% | 75.68 | 69.01% to 81.29% | 1.91 | 0.6413 |
| VACV A33R (NEGS Vs IMVANEX) | > 6.349 | 94.37 | 86.39% to 97.79% | 95.54 | 91.98% to 97.56% | 21.14 | 0.9865 |
| VACV B5R (NEGS Vs IMVANEX) | > 6.151 | 95.65 | 87.98% to 98.81% | 95.52 | 91.94% to 97.55% | 21.33 | 0.9885 |
| VACV D8L (NEGS Vs IMVANEX) | > 48.38 | 100 | 90.11% to 100.0% | 98.66 | 96.14% to 99.63% | 74.67 | 0.9968 |
| VACV L1R (NEGS Vs IMVANEX) | > 10.37 | 92.96 | 84.55% to 96.95% | 83.93 | 78.55% to 88.16% | 5.78 | 0.9545 |

648
 649
 650

651
 652
 653
 654
 655
 656
 657

Table 2: Median antibody concentrations (AU/ml) for all MPXV and VACV antigens. For paediatric negatives (n=215), 24 days post-dose one (PD1), 14 days post-dose two (PD2.1), with following longitudinal timepoints: 43 days (PD2.2), 43 days (PD2.2), 63 days (PD2.3), 84 days (PD2.4), 122 days (PD2.5), 157 days (PD2.6), 185 days (PD2.7), 220 days (PD2.8) and Mpox-infected (n=39). The corresponding cut-off for each antigen was assigned using ROC analysis. Cells highlighted in green show the median concentrations to be above the assigned cut-off.

| Median Antibody Concentration (AU/ml) | | | | | | | | | | | | | |
|---------------------------------------|---------|---------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|---------|
| Antigen | Species | Paediatric Negative | PD1 | PD2.1 | PD2.2 | PD2.3 | PD2.4 | PD2.5 | PD2.6 | PD2.7 | PD2.8 | MPXV22 | Cut off |
| A29L | MPXV | 0.3457 | 4.8 | 2.0 | 3.65 | 1.6 | 1.5 | 0.684 | 0.248 | 0.314 | 1.108 | 96.07 | 2.36 |
| A27L | VACV | 0.5878 | 5.8 | 4.3 | 5.7 | 2.8 | 2.7 | 0.865 | 0.357 | 0.327 | 2.59 | 64.52 | 2.11 |
| A35R | MPXV | 0.07092 | 7.0 | 736.8 | 216.1 | 101.2 | 145 | 48.18 | 5.073 | 5.093 | 12.77 | 2281 | 2.75 |
| A33R | VACV | 0.05385 | 14.5 | 1931 | 580.1 | 421.5 | 744.6 | 244 | 20.21 | 53.66 | 43.91 | 183.5 | 6.35 |
| B6R | MPXV | 0.03213 | 8.3 | 5523 | 1548 | 238.3 | 428.3 | 202.8 | 30.94 | 21.03 | 42.88 | 1617 | 2.67 |
| B5R | VACV | 0.1093 | 23.6 | 3052 | 2764 | 1024 | 864.6 | 656.4 | 83.78 | 295.6 | 485.2 | 1398 | 6.15 |
| E8L | MPXV | 0.3137 | 505.2 | 6787 | 9534 | 731 | 3370 | 1983 | 3229 | 3156 | 1491 | 2370 | 22.20 |
| D8L | VACV | 0.2977 | 5332 | 13100 | 14582 | 1916 | 752.1 | 3432 | 8200 | 5446 | 2401 | 1459 | 25.99 |
| M1R | MPXV | 2.264 | 80.0 | 1408 | 1021 | 221.3 | 186.1 | 71.74 | 110.8 | 86.58 | 156.3 | 24.64 | 11.19 |
| L1R | VACV | 1.94 | 121.7 | 908.4 | 780 | 114.6 | 439.2 | 204.6 | 167.3 | 91.41 | 195.6 | 19.57 | 10.37 |

658 Green = above cut-off
 659
 660
 661

662 **Supplementary Table 3: Correlation between MPXV/VACV antigens using Pearson r.** Significant values ($p \leq 0.05$) are indicated

663 with corresponding p values.

664

| | MPXV A29L | VACV A27L | MPXV A35R | VACV A33R | MPXV B6R | VACV B5R | MPXV E8L | VACV D8L | MPXV M1R | VACV L1R |
|-----------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| MPXV A29L | 1.000 | 0.393 ($p=2.13E-05$) | 0.026 | -0.047 | 0.036 | 0.161 | 0.019 | -0.041 | 0.145 | 0.103 |
| VACV A27L | 0.393 ($p=2.13E-05$) | 1.000 | -0.079 | -0.096 | -0.094 | -0.044 | -0.145 | -0.115 | -0.038 | -0.046 |
| MPXV A35R | 0.026 | -0.079 | 1.000 | 0.329 ($p=0.0005$) | 0.346 ($p=0.0003$) | 0.397 ($p=3.25E-05$) | 0.044 | -0.110 | -0.130 | -0.094 |
| VACV A33R | -0.047 | -0.096 | 0.329 ($p=0.0005$) | 1.000 | 0.568 ($p=1.00E-10$) | 0.569 ($p=1.93E-10$) | 0.148 | 0.086 | 0.033 | 0.232 ($p=0.0157$) |
| MPXV B6R | 0.036 | -0.094 | 0.346 ($p=0.0003$) | 0.568 ($p=1.00E-10$) | 1.000 | 0.734 ($p=3.76E-19$) | 0.191 | 0.018 | 0.195 ($p=0.0457$) | 0.353 ($p=0.0002$) |
| VACV B5R | 0.161 | -0.044 | 0.397 ($p=3.25E-05$) | 0.569 ($p=1.93E-10$) | 0.734 ($p=3.76E-19$) | 1.000 | 0.223 ($p=0.0370$) | 0.103 | 0.387 ($p=5.48E-05$) | 0.474 ($p=3.37E-07$) |
| MPXV E8L | 0.019 | -0.145 | 0.044 | 0.148 | 0.191 | 0.223 ($p=0.0370$) | 1.000 | 0.94 ($p=7.37E-43$) | 0.531 ($p=1.22E-07$) | 0.339 ($p=0.0012$) |
| VACV D8L | -0.041 | -0.115 | -0.110 | 0.086 | 0.018 | 0.103 | 0.94 ($p=7.37E-43$) | 1.000 | 0.481 ($p=1.79E-06$) | 0.278 ($p=0.0080$) |
| MPXV M1R | 0.145 | -0.038 | -0.130 | 0.033 | 0.195 ($p=0.0457$) | 0.387 ($p=5.48E-05$) | 0.531 ($p=1.22E-07$) | 0.481 ($p=1.79E-06$) | 1.000 | 0.914 ($p=6.85E-43$) |
| VACV L1R | 0.103 | -0.046 | -0.094 | 0.232 ($p=0.0157$) | 0.353 ($p=0.0002$) | 0.474 ($p=3.37E-07$) | 0.339 ($p=0.0012$) | 0.278 ($p=0.0080$) | 0.914 ($p=6.85E-43$) | 1.000 |

665

666